NCT05169437 2025-10-29
PAVO
Tempus AI
Phase 2 Terminated
Clinical Trials
12 trialsNCT05785039 2025-09-26
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT03219333 2024-08-27
EV-201
Astellas Pharma Inc
Phase 2 Completed
NCT02780687 2020-11-18
LUX-Bladder 1
Boehringer Ingelheim
Phase 2 Completed
NCT01599013 2015-12-08
JASINT1
Pierre Fabre Medicament
Phase 2 Completed
NCT02006667 2015-02-11
A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT02013765 2014-09-25
A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer
Hoffmann-La Roche
Phase 2 Terminated
NCT00034177 2009-06-04
Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or Recurrent TCC of the Urothelium
Achieve Life Sciences
Phase 2 Completed
NCT00191971 2007-11-06
2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen
Eli Lilly and Company
Phase 2 Completed
NCT00294476 2006-10-12
IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma
GammaCan
Phase 2 Unknown
NCT00034593 2006-07-19
A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
Eli Lilly and Company
Phase 2 Completed
NCT00035061 2006-07-19
A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium
Eli Lilly and Company
Phase 2 Completed